Dicot Pharma AB Logo

Dicot Pharma AB

Develops a potency agent for erectile dysfunction and premature ejaculation.

DICOTBT | SPGR

Overview

Corporate Details

ISIN(s):
SE0011178458 (+1 more)
LEI:
549300GX132RSE4OV407
Country:
Sweden
Address:
St Olofsgatan 11A, 753 21 Uppsala

Description

Dicot Pharma AB is a pharmaceutical company dedicated to developing a new generation of drugs for treating sexual dysfunctions. The company's primary focus is its drug candidate, LIB-01, a potency agent intended for the treatment of erectile dysfunction and premature ejaculation. Dicot Pharma aims for LIB-01 to offer significant advantages over existing therapies, including a longer duration of effect, fewer side effects, and effectiveness for a broader patient population. The company has completed a Phase 2a proof-of-concept study for LIB-01, which demonstrated positive results in improving erectile function with a sustained effect.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dicot Pharma AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dicot Pharma AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dicot Pharma AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-12 Tullbacken Aktiebolag Other Buy 35,000 40,250.00 SEK
2024-09-10 Amandus Jabin Other Sell 110,000 4,276,800.00 SEK
2024-09-03 Jörgen Larsson Other Other 315,000 N/A
2024-09-02 Patrick Lawlor Other Buy 77,500 1,158,625.00 SEK
2024-09-02 Oskar Hellström Other Buy 75,000 1,121,250.00 SEK
2024-09-02 Martin Walfisz Other Other 2,108,718 442,830.78 SEK
2024-08-31 Bonny Heeren Other Other 5,000,000 550,000.00 SEK
2024-08-30 Per-Anders Hedin Other Other 5,000,000 110,000.00 SEK
2024-08-30 Erik Markus Näsholm Other Other 2,000,000 42,600.00 SEK
2024-08-30 Greger Larsson Other Other 1,600,000 34,080.00 SEK

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.